ArticleAdvances in therapy2022

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.

Jean Grégoire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.